Chronic Heart Failure and Lipidology
We recommend
Inclisiran − a new addition to the arsenal of dyslipidemia treatment
At the XXIX Congress of the Czech Society of Internal Medicine ČLS JEP, held November 6−9, 2022 in Prague, lectures on innovative dyslipidemia therapy using the small interfering RNA molecule − inclisiran were presented at the Novartis company symposium.
Use of Inclisiran in a Patient in Secondary Cardiovascular Prevention
Lowering LDL cholesterol (LDL-c) is one of the primary goals for reducing cardiovascular (CV) risk…
Practical Experiences Using ZULP in Cardiology
The application of a product containing ferric carboxymaltose (FCM) or the use of a contrast agent…
Articles on this topic
How Will the New Player in Dyslipidemia Therapy Change the "Rules of the Game"?
Inclisiran, as an innovative drug indicated for adult patients with primary hypercholesterolem…
Impact of Initial RAAS Inhibitor on Hospitalization Risk in HFrEF Patients
Inhibition of the renin-angiotensin-aldosterone system (RAAS) is considered a key step in the…
ESC 2022: Can Modern Treatment of Acute Heart Failure Improve (Re)hospitalization Prevention?
Heart failure (HF) and the possibilities of its therapy were one of the frequently discussed…
Pharmacotherapy of Chronic Heart Failure with Reduced EF LV - Latest ESC Recommendations
The European Society of Cardiology (ESC) issued an update in 2021 for the diagnosis and…
Ivabradine and/or Sacubitril/Valsartan in the Treatment of Heart Failure with Reduced Ejection Fraction
Ivabradine and sacubitril/valsartan are used in the second line of therapy for heart failure…
INFOGRAPHIC: LDL Cholesterol - Recommended Target Values
Elevated levels of LDL cholesterol are a significant risk factor for cardiovascular diseases, which...
Reduction of LDL Cholesterol in the Prevention of Cardiovascular Morbidity and Mortality – Results of a Large Meta-Analysis
Elevated LDL cholesterol (LDL-c) is one of the main causes of atherosclerosis. The…
Does Sacubitril/Valsartan Prevent Myocardial Remodeling in Heart Failure Patients with Type 2 Diabetes?
The PROVE-HF study demonstrated reverse myocardial remodeling in patients with chronic heart…
INFOGRAPHIC: Prevention and Management of Hypotension During Sacubitril/Valsartan Treatment
Despite the undeniable benefits of sacubitril/valsartan in terms of morbidity and mortality in…
Hypotension during treatment with sacubitril/valsartan: practical tips for prevention and management
Despite the undeniable benefits of sacubitril/valsartan in terms of morbidity and mortality in…
1
2
Subscribe
Most read on this topic
Journal on this topic
Related topic
Interesting links
Most read on this topic
- INFOGRAPHIC: LDL Cholesterol - Recommended Target Values
- Inclisiran − a new addition to the arsenal of dyslipidemia treatment
- Pharmacotherapy of Chronic Heart Failure with Reduced EF LV - Latest ESC Recommendations
- The heart transplantation
- Practical Experiences Using ZULP in Cardiology
- How to Achieve Left Ventricular Reverse Remodeling and Improve Outcomes in Heart Failure? Summary from HFA ESC Webinar
Journal on this topic
Related topic
Interesting links